This LETTER TO THE EDITOR provides the insights regarding the use of a replication-defective adenovirus-mediated IFN therapy for cancer treatment and explains why a positive clinical benefit-risk profile can be expected from using this approach. This evidence concerns the gene IFNA1 and cancer.